MedTrace Logo

Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes

NCT00401622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2019-05-15

Study results available
· View outcomes & findings →

Summary

Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

OneTouch® Ultra®2 System

Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program

BEHAVIORAL

Standard care

Standard education and self-monitoring of blood glucose performed with traditional meter systems

Sponsors & Collaborators

  • Synexus(UK)

    collaborator UNKNOWN

  • CPS(UK)

    collaborator UNKNOWN

  • Battelle CRO(US)

    collaborator UNKNOWN

  • RPS CRO(US)

    collaborator UNKNOWN

  • Robertson Centre For Biostatistics (UK)

    collaborator UNKNOWN

  • LifeScan

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-01
Primary Completion
2009-01-01
Completion
2009-01-01

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401622 on ClinicalTrials.gov